Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
Type:
Grant
Filed:
April 21, 2023
Date of Patent:
May 27, 2025
Assignee:
Genentech, Inc.
Inventors:
X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
Abstract: The present application relates to systems and methods for purifying polypeptides, such as His-tagged polypeptides, using immobilized metal chelate affinity chromatography (IMAC). The method includes loading a composition comprising the polypeptide onto a IMAC matrix; eluting the polypeptide from the first IMAC matrix; conducting a buffer exchange to remove the elution buffer from the first eluate; loading the first eluate from the buffer exchange onto a second IMAC matrix; eluting the polypeptide from the second IMAC matrix; and optionally purifying the eluate from the second IMAC matrix using size exclusion chromatography. In some aspects, the method is fully automated.
Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Type:
Application
Filed:
January 17, 2025
Publication date:
May 15, 2025
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
Inventors:
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Abstract: Medical image(s) are input into a detection network to generate mask(s) identifying a set of regions within the medical image(s), where the detection network predicts that each region identified in the mask(s) includes a depiction of a tumor of one or more tumors within the subject. For each region, the region of the medical image(s) is processed using a tumor segmentation network to generate one or more tumor segmentation boundaries for the tumor present within the subject. For each tumor and by using a plurality of organ-specific segmentation networks, an organ is determined within which at least part of the tumor is located. An output is generated based on the one or more tumor segmentation boundaries and locations of the organs within which at least part of the one or more tumors are located.
Type:
Grant
Filed:
June 16, 2022
Date of Patent:
May 13, 2025
Assignee:
GENENTECH, INC.
Inventors:
Nils Gustav Thomas Bengtsson, Richard Alan Duray Carano, Alexander James Stephen Champion De Crespigny, Jill Osborn Fredrickson, Mohamed Skander Jemaa
Abstract: Naphthyridine compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
May 13, 2025
Assignee:
Genentech, Inc.
Inventors:
Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
Abstract: A method of preparing a prefilled syringe is disclosed that includes obtaining a syringe barrel and a needle adaptor cap assembled on the tip of the syringe barrel, wherein the needle adaptor cap has a rubber element tightly sealing the orifice of the tip of the syringe barrel and the syringe barrel together with the needle adaptor cap assembled on the tip of the syringe barrel is sterilized by a first sterilizing. Filling a drug substance into an interior of the syringe barrel and sealing the interior of the syringe barrel. Packaging the syringe barrel with a rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel. Providing a second external surface sterilizing of the packaged syringe barrel with the rubber stopper sealing the interior thereof and the needle adaptor cap assembled on the tip of the syringe barrel.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
May 13, 2025
Assignees:
F. HOFFMANN-LA ROCHE AG, GENENTECH, INC.
Inventors:
Markus Hemminger, Ulla Grauschopf, Frank Bamberg, Mayumi Bowen, Robert Müller, Flora Felsovalyi, Denny Christensen
Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
Abstract: The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
Type:
Grant
Filed:
May 13, 2022
Date of Patent:
May 6, 2025
Assignee:
Genentech, Inc.
Inventors:
Carol Elaine O'Hear, Yasuhiro Oki, Iris Tranthuyngan To
Abstract: Provided herein are methods and host cells for producing a polypeptide containing two chains, such as an antibody, half-antibody, antibody fragment, or one-armed antibody. The methods and host cells allow for two-chain polypeptide production using expression of polynucleotides encoding the polypeptide chains from extra-chromosomal polynucleotide(s), and expression of one or more chaperone protein(s) (e.g., peptidyl-prolyl isomerases and/or protein disulfide oxidoreductases) from the host cell chromosome using non-native combination(s) of promoters and translational units encoding a chaperone protein.
Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
Type:
Application
Filed:
December 20, 2024
Publication date:
May 1, 2025
Applicant:
Genentech, Inc.
Inventors:
Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
Type:
Application
Filed:
August 30, 2024
Publication date:
May 1, 2025
Applicant:
Genentech, Inc.
Inventors:
Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA
Abstract: The present disclosure relates to methods, cells and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interests, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have modulated lactogenic activity. The present disclosure also relates to methods and compositions for modulating pyruvate kinase muscle (PKM) expression (e.g., PKM-1 expression) in a mammalian cell to thereby reduce or eliminate the lactogenic activity of the cell, as well compositions comprising a cell having reduced or eliminated lactogenic activity and methods of using the same.
Type:
Grant
Filed:
September 29, 2020
Date of Patent:
April 29, 2025
Assignee:
GENENTECH, INC.
Inventors:
Shahram Misaghi, Masaru Ken Shiratori, Bradley Richard Snedecor, Michael W. Laird
Abstract: The invention provides a compound represented by the either of the following structural formulas, or a pharmaceutically acceptable salt, or a stereoisomer thereof, useful for treating cancer.
Abstract: The present disclosure relates to benzothiazole compounds and to methods of using such compounds. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.
Type:
Application
Filed:
October 11, 2024
Publication date:
April 24, 2025
Applicant:
Genentech, Inc.
Inventors:
Jakob FUHRMANN, Alberto Emilio GOBBI, Joachim RUDOLPH
Abstract: Particular embodiments provide a method for anomaly detection in images of tissue. An image processing system may receive an image of a tissue sample. A set of tiles may be generated from the image of the tissue sample. The set of tiles may be input into an anomaly detection model comprising a generator model comprising functional skip-connections and a Markovian discriminator model. The anomaly detection model may be trained to isolate a feature space of normal tissue samples. Anomaly scores may be computed for the set of tiles, and an assessment may be generated for the image of the tissue sample based on the anomaly scores for the set of tiles. The assessment may include a reconstructed heatmap of the image of the tissue sample, wherein colors of the heatmap are selected based on the anomaly scores.
Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.